Eli Lilly and NVIDIA Are Building a $1 Billion Lab to Put AI Scientists Next to Human Ones
At the J.P. Morgan Healthcare Conference on January 12, 2026, NVIDIA and Eli Lilly announced a five-year, $1 billion partnership...
Month: August 2026
GE HealthCare’s $2.3 Billion Bet: Buying Intelerad to Build an AI Imaging Empire Beyond the Hospital
GE HealthCare closed a $2.3 billion all-cash acquisition of Intelerad Medical Systems on March 18, 2026, absorbing a Montreal-based imaging...
Aidoc Wins FDA Clearance for a Single AI Model That Triages 14 Acute Conditions From One CT Scan
For most of the last decade, AI in radiology has meant one algorithm for one problem: a model that flags...
A 175,000-Woman UK Trial Just Made the Case for Replacing One of Two Radiologists With AI
Britain's breast cancer screening program has long relied on a safeguard considered close to sacred in radiology: every mammogram is...
AI Software Spotted Breast Cancer on Mammograms Up to Six Years Before Diagnosis, Swedish Study Finds
Every mammogram a radiologist reads carries the possibility of a miss — a faint density or asymmetry too subtle to...
The Secretive $1 Billion Biotech Betting Everything on a 4.9 Billion-Parameter ‘Virtual Cell’
When Xaira Therapeutics launched in 2024 with close to $1 billion in funding and a $4 billion valuation, it did...
Tempus AI Swings to Profit, Raises Guidance to $1.6 Billion, and Buys Its Way Into Cancer Blood Tests
For years, Tempus AI has been one of the most closely watched — and most doubted — names in AI-driven...
Nurses, Not Hospital Executives, Are Getting Paid to Study Whether AI Actually Works
Most decisions about which AI tools enter a hospital are made far from the bedside — in boardrooms, procurement offices,...
OpenEvidence Doubles to a $12 Billion Valuation as Doctors Ditch UpToDate for AI Chat
Three years ago, OpenEvidence was an idea sketched out by a former hedge-fund quant and a machine-learning researcher who thought...
Roche Just Moved Its First AI-Found Brain-Disease Target Out of the Lab
Roche and Recursion Pharmaceuticals announced on August 5, 2026 that they have advanced the first drug target to emerge from...
